Skip to main content

ALC · Alcon Inc

Track ALC — free
$64.75 -0.69 (-1.05%) At close · Sep 30
Market Cap
$31.52B
Shares
483.40M
Volume · Sep 30 1.6M Avg daily vol (3M) 1.92M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$64.75 Open$65.26 Day$64.51–65.28 52W close$62.02–87.18 Avg vol 30d1.5M Short int17.5M · 3.6% float · 11.3d Short vol49% Last earningsNov 11, 2026 DataJan 2020–Sep 2026

Up next

Next earnings call
Nov 11, 2026 Scheduled · in 6 wks
call held Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+4.0%
Year over year
Operating margin
13.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.7%
Year over year · more shares
Price change (1Y)
-11.7%
Trailing year
Short interest
3.6%
Latest settlement · 11.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Low
Market backdrop VIX 16.3 · calm Equity put/call 0.53
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −12%
below
Price vs 50-day avg −7%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 11%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −10%
trailing
6-month return −16%
trailing
YTD return −18%
this year
Relative strength −29%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $70 › 200d $73 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +80 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.62% of float · ▲ +20.0% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
639 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Excellent
Revenue growth +10%
Y/Y
Gross margin 77%
expanding
EPS growth +9%
Y/Y
Free cash flow $2.1B
Buyback $750.0M
authorized
Balance sheet $2.5B
net cash
Quant / Vol
risk profile
Low
Volatility 28%
annualized · 1-yr
Max drawdown −29%
past year
ATR 1.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 11, 2026
2026
Core diluted EPS growth Non-GAAP 12% – 15%
third quarter
Anticipated refund from the U.S. government $60M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−12% Bearish
Price vs 50-day avg
−7% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
11% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $70 › 200d $73 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +80 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.62% of float · ▲ +20.0% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
639 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $62 Now $65 · 11% Range high $87
vs 200-day avg -12% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ALC
Alcon Inc
this stock
$31.52B -17.8% +10.5% — 3.6%
ISRG
Intuitive Surgical Inc
$143.14B -28.2% +20.5% 46.5 2.3%
BDX
Becton Dickinson & Co
$49.57B — +8.2% — 4.2%
MDLN
Medline Inc.
$45.62B -17.4% +11.5% — 3.1%
RMD
Resmed Inc
$32.02B -8.2% +13.4% 21.3 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
639
% held
52.9%
Net QoQ
+18.8M sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
69
View
Short & Settlement
Short Interest Rising
Shares short
17.5M
Days to cover
11.3d
Change
+2.9M sh
View
Short Volume
Short vol %
49%
As of
Sep 30, 2026
Short Total
View
Fails to Deliver
FTD shares
85.8K
Value
$5.7M
As of
Sep 11, 2026
View
Off-Exchange
Off-exchange %
37.8%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Julie Johnson
Amount
$1.0K–$15.0K
Traded
Mar 3, 2025
View
Financials
Financials
EPS diluted
$7.27
View
Buybacks
Authorized
$750.0M
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 10, 2026
This year
7
View
Proposed Sales
Value
$209.6K
Shares
2.4K
Filed
Feb 26, 2026
View
Earnings & Events
Earnings Calls Upcoming
Next call
Nov 11, 2026
Last call
Aug 11, 2026
View
Investor Relations
Latest news
Alcon and RxSight Announce Collab…
Published
Jul 6, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
ALC -1.0% -9.8% -16.3% -10.1% -17.8%
SPY -0.7% +0.1% +12.2% -0.6% +11.8%
vs SPY -0.3% -9.9% -28.5% -9.6% -29.7%

Capital returns

Buyback program · as of Feb 25, 2025
Authorized
$750.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1167379 CUSIP H01301128 13F (30d) 24 filings 15 filers Visit website Investor relations